The medication will be sold under the brand name Journavx for $15.50 per pill, according to Vertex Pharmaceuticals, the company that developed the new drug. The FDA's sign-off on the medication ...

On January 30, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

The FDA approved Journavx on Thursday following a pair of clinical trials on 874 participants with moderate to severe acute pain following abdominoplasty — commonly known as a "tummy tuck ...

The US FDA has approved Journavx, a new pain reliever without the risks for addiction or overdose linked to drugs like Vicodin and OxyContin.

The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain ... drug pipeline that involves winning FDA approval for multiple drugs across several ...

The United States Food and Drug Administration (FDA) has approved a new non-opioid prescription medication, Journavx (suzetrigine), for adults with moderate to severe acute pain. Developed by ...

The use of Journavx for moderate to severe pain has not been studied beyond 14 days. The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to ...

AlgoTherapeutix blames a “strong placebo effect” for the mid-stage failure for its pain gel ATX01, but the company still ...

In two randomized clinical trials evaluating pain control following abdominoplasty and bunionectomy, Journavx demonstrated ...

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under the brand name Journavx.